Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseaseKT-621 ...
eLife1d
Identification of pharmacological inducers of a reversible hypometabolic state for whole organ preservation
Repurposing of a drug designed for pain relief can quickly and reversibly slow biochemical and metabolic activities in cells and organs and could facilitate organ transplantation and prevent tissue ...
NPR Illinois1d
Motel 6 is sold to an Indian hotel company for $525 million
The sale to Oyo, a travel business, will include the Studio 6 motel brand, which caters to customers seeking extended stays.
thecardiologyadvisor.com2d
Interleukin-6 Levels Predict Obesity-Related Cancer Risk in Type 2 Diabetes
Interleukin-6 levels were associated with an increased risk for obesity-related cancer among individuals with newly diagnosed type 2 diabetes.
News Medical5d
Childhood adversity linked to elevated health risks, differing by sex and stress
Researchers assess the heterogeneous effects of childhood adversity on disease biomarkers and health conditions in adulthood.
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...